Q2 FY2026 EarningsQ2 FY26 results missed consensus across key financial metrics. Revenue of $3.64M was 4.46% below the $3.81M expectation, while gross margin compressed to 51.36% (vs. 55.00% expected) due to pricing pressure and new tariffs. The net loss of -$7.48M and EPS of -$0.15 both underperformed expectations, driven by a 46% YoY surge in operating expenses linked to clinical trials and public company costs. Management anticipates FDA clearance for AI Highlights™ by Q3-end, representing a critical near-term catalyst.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: CapsoVision(CV) the Revenue is 3.643 M (+9.89%), Miss estimate;the EBIT is -7.58 M (-62.98%), Miss estimate;the EPS is -0.15 (-51.67%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B9.89%
0.00B15.02%
-0.00B5.13%
EBITMiss expectations
-0.01B62.98%
-0.01B31.65%
-0.00B31.33%
EPSMiss expectations
-0.1551.67%
-0.1331.45%
-0.020020.22%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf